Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Franke EK and Luban J | Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. | 1996 | Virology | pmid:8806510 |
Stremlau M et al. | Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. | 2006 | Virology | pmid:16643975 |
Goldfeld AE et al. | Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. | 1995 | Virology | pmid:7538254 |
Zhao W et al. | Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. | 2006 | Virology | pmid:16828834 |
MistrÃková J et al. | Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). | 1999 | Viral Immunol. | pmid:10532652 |
Gambarino S et al. | Human Cytomegalovirus Impact on mir-146a Expression Levels in Kidney Transplant Patients. | 2016 | Viral Immunol. | pmid:27077822 |
Shen ZY et al. | Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. | 2012 | Viral Immunol. | pmid:22946668 |
Mortola E et al. | The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. | 1998 | Vet. Res. Commun. | pmid:10066129 |
Tanaka Y et al. | Suppression of feline coronavirus replication in vitro by cyclosporin A. | 2012 | Vet. Res. | pmid:22546085 |
Kano R et al. | Treatment of sterile panniculitis in a dog. | 2004 | Vet. Rec. | pmid:15134169 |
Ofri R et al. | Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. | 2009 | Vet. J. | pmid:17950639 |
Sestak K et al. | Tacrolimus-FK506 induced immunosuppression in gnotobiotic piglets. | 2000 | Vet. Immunol. Immunopathol. | pmid:11137126 |
Marsella R et al. | Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. | 2004 | Vet. Dermatol. | pmid:15500481 |
Mauldin EA et al. | Proliferative and necrotizing otitis externa in four cats. | 2007 | Vet. Dermatol. | pmid:17845627 |
Hilton H et al. | Evaluation of four topical preparations for the treatment of cannon hyperkeratosis in a horse. | 2008 | Vet. Dermatol. | pmid:19055613 |
Marsella R and Nicklin CF | Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. | 2002 | Vet. Dermatol. | pmid:12174182 |
Banovic F et al. | Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus. | 2017 | Vet. Dermatol. | pmid:28439997 |
Rosenkrantz WS | Pemphigus: current therapy. | 2004 | Vet. Dermatol. | pmid:15030557 |
Olivry T et al. | Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. | 2010 | Vet. Dermatol. | pmid:20456716 |
Kelley LS et al. | Safety and tolerability of 0.1% tacrolimus solution applied to the external ear canals of atopic beagle dogs without otitis. | 2010 | Vet. Dermatol. | pmid:20609208 |